Atossa Therapeutics (ATOS) 10-Q 14 Aug 23 2023 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Aug. 10, 2023
Document Information [Line Items]
Entity Central Index Key	0001488039
Entity Registrant Name	ATOSSA THERAPEUTICS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-35610
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-4753208
Entity Address, Address Line One	107 Spring Street
Entity Address, Postal Zip Code	98104
Entity Address, City or Town	Seattle
Entity Address, State or Province	WA
City Area Code	206
Local Phone Number	588-0256
Title of 12(b) Security	Common Stock, $0.18 par value
Trading Symbol	ATOS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		125,785,200

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 99,390	$ 110,890
Restricted cash	110	110
Prepaid expenses	5,759	4,031
Research and development rebate receivable	737	743
Other current assets	7	2,423
Total current assets	106,003	118,197
Investment in equity securities	1,710	4,700
Other assets	642	635
Total Assets	108,355	123,532
Current liabilities
Accounts payable	1,174	2,965
Accrued expenses	803	1,059
Payroll liabilities	1,455	1,525
Other current liabilities	46	19
Total current liabilities	3,478	5,568
Total Liabilities	3,478	5,568
Commitments and contingencies (Note 15)
Stockholders' equity
Series B convertible preferred stock - $0.001 par value; 10,000 shares authorized; 1 share issued and outstanding as of June 30, 2023 and December 31, 2022	0	0
Common stock - $0.18 par value; 175,000 shares authorized; 126,505 and 126,624 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively	22,792	22,792
Additional paid-in capital - common stock	253,960	250,784
Treasury stock, at cost; 119 and 0 shares of common stock at June 30, 2023 and December 31, 2022, respectively	(152)	0
Accumulated deficit	(172,305)	(156,194)
Total Stockholders' Equity	104,877	117,964
Total Liabilities and Stockholders' Equity	108,355	123,532
Series B Preferred Stock [Member]
Stockholders' equity
Additional paid-in capital - Series B convertible preferred stock	$ 582	$ 582

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares shares in Thousands	Jun. 30, 2023	Dec. 31, 2022
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	10,000	10,000
Preferred stock, issued (in shares)	1	1
Preferred stock, outstanding (in shares)	1	1
Common stock, par value (in dollars per share)	$ 0.18	$ 0.18
Common stock, authorized (in shares)	175,000	175,000
Common stock, issued (in shares)	126,505	126,624
Common stock, outstanding (in shares)	126,505	126,624
Treasury stock, shares (in shares)	119	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses
Research and development	$ 3,705	$ 3,433	$ 7,213	$ 4,937
General and administrative	4,088	3,162	7,678	6,411
Total operating expenses	7,793	6,595	14,891	11,348
Operating loss	(7,793)	(6,595)	(14,891)	(11,348)
Impairment charge on investment in equity securities	(2,990)	0	(2,990)	0
Interest income	983	11	1,833	13
Other expense, net	(30)	(88)	(63)	(122)
Loss before income taxes	(9,830)	(6,672)	(16,111)	(11,457)
Income taxes	0	0	0	0
Net loss	$ (9,830)	$ (6,672)	$ (16,111)	$ (11,457)
Loss per share of common stock - basic and diluted (in dollars per share)	$ (0.08)	$ (0.05)	$ (0.13)	$ (0.09)
Weighted average shares outstanding - basic and diluted (in shares)	126,623	126,624	126,623	126,624

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock Additional Paid-in Capital [Member]	Common Stock Outstanding [Member]	Common Stock [Member]	Common Stock, Additional Paid-in Capital [Member]	Treasury Stock, Common [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2021	1		126,624
Balance at Dec. 31, 2021	$ 0	$ 582		$ 22,792	$ 243,996	$ 0	$ (129,234)	$ 138,136
Compensation cost for stock options granted	0	0		0	1,806	0	0	1,806
Net loss	$ 0	0		0	0	0	(4,785)	(4,785)
Balance (in shares) at Mar. 31, 2022	1		126,624
Balance at Mar. 31, 2022	$ 0	582		22,792	245,802	0	(134,019)	135,157
Balance (in shares) at Dec. 31, 2021	1		126,624
Balance at Dec. 31, 2021	$ 0	582		22,792	243,996	0	(129,234)	138,136
Net loss								(11,457)
Balance (in shares) at Jun. 30, 2022	1		126,624
Balance at Jun. 30, 2022	$ 0	582		22,792	247,573	0	(140,691)	130,256
Balance (in shares) at Mar. 31, 2022	1		126,624
Balance at Mar. 31, 2022	$ 0	582		22,792	245,802	0	(134,019)	135,157
Compensation cost for stock options granted	0	0		0	1,771	0	0	1,771
Net loss	$ 0	0		0	0	0	(6,672)	(6,672)
Balance (in shares) at Jun. 30, 2022	1		126,624
Balance at Jun. 30, 2022	$ 0	582		22,792	247,573	0	(140,691)	130,256
Balance (in shares) at Dec. 31, 2022	1		126,624
Balance at Dec. 31, 2022	$ 0	582		22,792	250,784	0	(156,194)	117,964
Compensation cost for stock options granted	0	0		0	1,573	0	0	1,573
Net loss	$ 0	0		0	0	0	(6,281)	(6,281)
Balance (in shares) at Mar. 31, 2023	1		126,624
Balance at Mar. 31, 2023	$ 0	582		22,792	252,357	0	(162,475)	113,256
Balance (in shares) at Dec. 31, 2022	1		126,624
Balance at Dec. 31, 2022	$ 0	582		22,792	250,784	0	(156,194)	117,964
Net loss								(16,111)
Balance (in shares) at Jun. 30, 2023	1		126,505
Balance at Jun. 30, 2023	$ 0	582		22,792	253,960	(152)	(172,305)	104,877
Balance (in shares) at Mar. 31, 2023	1		126,624
Balance at Mar. 31, 2023	$ 0	582		22,792	252,357	0	(162,475)	113,256
Compensation cost for stock options granted	0	0		0	1,603	0	0	1,603
Net loss	$ 0	0		0	0	0	(9,830)	(9,830)
Common stock repurchased (in shares)	0		(119)
Common stock repurchased	$ 0	0		0	0	(152)	0	(152)
Balance (in shares) at Jun. 30, 2023	1		126,505
Balance at Jun. 30, 2023	$ 0	$ 582		$ 22,792	$ 253,960	$ (152)	$ (172,305)	$ 104,877

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (9,830)	$ (6,672)	$ (16,111)	$ (11,457)
Adjustments to reconcile net loss to net cash used in operating activities
Compensation cost for stock options granted			3,176	3,577
Depreciation and amortization			6	4
Impairment charge on investment in equity securities	2,990	0	2,990	0
Disposal of assets			0	1
Changes in operating assets and liabilities:
Prepaid expenses			(1,728)	(2,816)
Research and development rebate receivable			6	172
Other current assets			2,416	(377)
Other assets			0	(597)
Accounts payable			(1,943)	335
Accrued expenses			(256)	630
Payroll liabilities			(70)	(309)
Other current liabilities			27	10
Net cash used in operating activities			(11,487)	(10,827)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of furniture and equipment			(13)	(13)
Net cash used in investing activities			(13)	(13)
CASH FLOWS FROM FINANCING ACTIVITIES
Net cash used in financing activities			0	0
NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH			(11,500)	(10,840)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE			111,000	136,487
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	99,500	125,647	99,500	125,647
SUPPLEMENTAL DISCLOSURES
Cash and cash equivalents	99,390	125,537	99,390	125,537
Restricted cash	110	110	110	110
Total cash, cash equivalents and restricted cash shown in the Condensed Consolidated Statements of Cash Flows	$ 99,500	$ 125,647	99,500	125,647
NONCASH INVESTING AND FINANCING ACTIVITIES
Unsettled trades for repurchase of common stock			$ 152	$ 0

Note 1 - Nature of Operations

Note 1 - Nature of Operations	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Nature of Operations [Text Block]	NOTE 1: Atossa Therapeutics, Inc. (the Company) was incorporated on April 30, 2009, December 31.

Note 2 - Liquidity and Capital

Note 2 - Liquidity and Capital Resources	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Liquidity and Capital Resources [Text Block]	NOTE 2: The Company has incurred net losses and negative operating cash flows since inception. For the six June 30, 2023 June 30, 2023 not one no may

Note 3 - Summary of Accounting

Note 3 - Summary of Accounting Policies	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	NOTE 3: Basis of Presentation The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form 10 10 01 X. not no 10 December 31, 2022 not In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included and have been prepared on the same basis as the annual consolidated financial statements. Operating results for the six June 30, 2023 not may December 31, 2023. Reclassification Interest income has been reclassified from prior period amounts to conform to the current year presentation. Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Segments The Company operates as a single Cash and Cash Equivalents Cash and cash equivalents include unrestricted cash and all highly liquid instruments with maturities of three Investments in Equity Securities The Company currently has one not ASC 321 Equity Once a decline in fair value is determined, an impairment charge is recorded to Impairment charge on investment in equity securities in the Condensed Consolidated Statement of Operations and a new basis in the investment is established. If market, industry, and/or investee conditions deteriorate, we may 4. Fair Value Measurements The Company records financial assets and liabilities measured on a recurring and non-recurring basis, as well as all non-financial assets and liabilities subject to fair value measurement at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The accounting guidance establishes a hierarchy for inputs used in measuring fair value that minimizes the use of unobservable inputs by requiring the use of observable market data when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on active market data. Unobservable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. The fair value hierarchy is broken down into the three ● Level 1 ● Level 2 ● Level 3 no The carrying amounts reflected in the accompanying Condensed Consolidated Balance Sheets for cash and cash equivalents, restricted cash, prepaid expenses, research and development rebate receivable, other current assets, accounts payable, accrued expenses, payroll liabilities and other current liabilities approximate their fair values due to their short-term nature. Refer to Note 10. Research and Development Research and development (R&D) costs are generally expensed as incurred. R&D expenses include, for example, manufacturing expenses for the Company's drugs under development, expenses associated with preclinical studies, clinical trials and associated salaries, bonuses, stock-based compensation and benefits. The Company has entered into various research and development contracts with research institutions, clinical research organizations (CROs), clinical manufacturing organizations (CMOs) and other companies. Payments for these activities are based on the terms of the individual agreements, which may may R&D expenses also include an allocation of the CEO's salary and related benefits, including bonus and non-cash stock-based compensation expense, based on an estimate of his total hours spent on R&D activities. The Company's CEO is involved in the development of the Company's drug candidates and oversight of the related clinical trial activity. Stock-based Payments The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers, non-employee directors, and other key persons providing services to the Company, currently limited to stock options. Stock compensation expense is based on the estimated grant date fair value and is recognized as an expense over the requisite service period. The Company has made a policy election to recognize forfeitures when they occur. The fair value of each stock option grant is estimated using the Black-Scholes option-pricing model, which requires assumptions regarding the expected volatility of the stock options, the expected life of the options, an expectation regarding future dividends on the Company’s common stock, and an estimate of the appropriate risk-free interest rate. The Company’s expected common stock price volatility assumption is based upon the historical volatility of its stock price. The Company has elected the simplified method for the expected life assumption for stock option grants, which averages the contractual term of the options of 10 years with the vesting term, typically one four not no Foreign Currency Translation and Transactions The majority of the Company's operations occur in entities that have the U.S. dollar as their functional currency. Subsidiary assets and liabilities translated into U.S. dollars at rates of exchange in effect at the end of the period. Expense amounts are translated using the average exchange rates for the period.

Note 4 - Investment in Equity S

Note 4 - Investment in Equity Securities	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Investments in Non-marketable Equity Securities Disclosure [Text Block]	NOTE 4: On December 23, 2022, not The Company considered qualitative impairment factors in determining if there were any signs of impairment of this investment on the balance sheet dates. Specifically, the Company considered the additional adverse changes in the general market condition of the industry in which DCT operates and continued concerns about the investee’s ability to continue as a going concern, due to negative cash flows from operations during the three six June 30, 2023. June 30, 2023 3 June 30, 2023. June 30, 2023 The following table summaries the changes in the Company's Level 3 three six June 30, 2023: Investment in equity securities: Beginning balance January 1, 2023 $ 4,700 Impairment charge on investment in equity securities (2,990 ) Ending balance June 30, 2023 $ 1,710

Note 5 - Restricted Cash

Note 5 - Restricted Cash	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Restricted Assets Disclosure [Text Block]	NOTE 5: The Company's restricted cash balance of $110 June 30, 2023 December 31, 2022

Note 6 - Prepaid Expenses

Note 6 - Prepaid Expenses	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Prepaid Expenses [Text Block]	NOTE 6: Prepaid expenses consisted of the following: As of June 30, As of December 31, 2023 2022 Prepaid research and development $ 4,918 $ 3,480 Prepaid insurance 509 387 Professional services 191 130 Other 141 34 Total prepaid expenses $ 5,759 $ 4,031

Note 7 - Research and Developme

Note 7 - Research and Development Rebate Receivable	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Research and Development Tax Rebate Receivable [Text Block]	NOTE 7: On May 23, 2017, $0.435 80% $0.485 four $2,028 20 During the three six June 30, 2023 three six June 30, 2022, six June 30, 2023 six June 30, 2022 June 30, 2023 December 31, 2022, three six June 30, 2023, 2022,

Note 8 - Accrued Expenses

Note 8 - Accrued Expenses	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Accrued Liabilities Disclosure [Text Block]	NOTE 8: Accrued expenses consisted of the following: As of June 30, As of December 31, 2023 2022 Research and development $ 559 $ 1,038 Professional Services 244 21 Total accrued liabilities $ 803 $ 1,059

Note 9 - Payroll Liabilities

Note 9 - Payroll Liabilities	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	NOTE 9: Payroll liabilities consisted of the following: As of June 30, As of December 31, 2023 2022 Accrued bonuses $ 507 $ 1,060 Accrued vacation 232 224 Accrued payroll 716 241 Total payroll liabilities $ 1,455 $ 1,525

Note 10 - Fair Value of Financi

Note 10 - Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 10: The following tables present the Company’s fair value hierarchy for all of its financial assets and liabilities, by major security type, measured at fair value on a recurring basis: June 30, 2023 Estimated Fair Value Level 1 Level 2 Level 3 Assets: Money market account $ 97,182 $ 97,182 $ - $ - December 31, 2022 Estimated Fair Value Level 1 Level 2 Level 3 Assets: Money market account $ 102,681 $ 102,681 $ - $ - There were no 1 3 three six June 30, 2023. not June 30, 2023 December 31, 2022.

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Equity [Text Block]	NOTE 11: EQUITY Common Stock The Company is authorized to issue a total of 185,000 shares of stock, consisting of 175,000 shares of common stock, par value $0.18 per share, and 10,000 shares of preferred stock, par value $0.001 per share. On May 19, 2014, May 26, 2014 one 1 2 Share Repurchases On June 27, 2023, December 31, 2023, may June 30, 2023, not June 30, 2023, Series Convertible Preferred Stock The Company has designated 750 shares of Series A junior participating preferred stock, par value $0.001 per share, 4 shares of Series A convertible preferred stock, par value $0.001 per share, 25 shares of Series B convertible preferred stock, par value $0.001 per share, and 20 shares of Series C convertible preferred stock, par value $0.001 per share, through the filings of certificates of designation with the Delaware Secretary of State. No shares of Series A junior participating preferred stock, Series A convertible preferred stock or Series C convertible preferred stock were outstanding as of June 30, 2023 December 31, 2022 Series B Convertible Preferred Stock Conversion. not Fundamental Transactions. Dividends. Voting Rights. no Liquidation Preference . Redemption Rights. not not Conversion of Series B Convertible Preferred Stock During the three six June 30, 2023 2022 no 2021 2020 The terms and conditions of the warrants are as follows: Exercisability 4 Cashless Exercise no not may Exercise Price one not may no Transferability may may Exchange Listing not Rights as Stockholder not Warrants Outstanding As of June 30, 2023 Outstanding Warrants to Purchase Shares Exercise Price Per Share Expiration Date December 2020 warrants 6,490 $ 1.00 December 11, 2024-June 21, 2025 January 2021 warrants 4,500 $ 1.055 July 8, 2025 March 2021 warrants 10,525 $ 2.88 September 22, 2025 21,515 Warrant Activity There were no three six June 30, 2023 2022

Note 12 - Net Loss Per Share

Note 12 - Net Loss Per Share	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 12: Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back any convertible preferred dividends. Diluted net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock that would have been outstanding during the period assuming the issuance of shares of common stock for all potential dilutive shares of common stock outstanding. Potential shares of common stock consist of potential future exercises of outstanding stock options and common stock warrants. Because the inclusion of potential shares of common stock would be anti-dilutive for all periods presented, they have been excluded from the calculation. The Company’s common stock warrants and preferred stock contractually entitle the holders of such securities to participate in dividends but do not not not three six June 30, 2023 2022 The following table sets forth the weighted average number of common share equivalents excluded from the calculation of net loss per diluted share because including them would be anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Options to purchase common stock 17,828 13,337 16,294 12,219 Series B convertible preferred stock 165 165 165 165 Warrants to purchase common stock 21,515 22,009 21,515 22,142 39,508 35,511 37,974 34,526

Note 13 - Income Taxes

Note 13 - Income Taxes	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 13: Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No income tax liabilities existed as of June 30, 2023 December 31, 2022

Note 14 - Concentration of Cred

Note 14 - Concentration of Credit Risk	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	NOTE 14: Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of deposits of cash and cash equivalents including those deposited in money market deposit accounts. Accounts at each institution that contain specified types of deposits are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250. June 30, 2023 December 31, 2022

Note 15 - Commitments and Conti

Note 15 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 15: Lease Commitments The Company evaluates all contractual agreements at inception to determine if they contain a lease. Lease liabilities are measured at the present value of lease payments not 12 no The Company's operating lease consists of an office lease. On November 22, 2022, 12 no January 1, 2023. June 26, 2023, 12 July 1, 2023, no The Company had lease expense under its office lease during the three six June 30, 2023 three six June 30, 2022 Litigation and Contingencies The Company is subject to legal proceedings and claims that arise in the normal course of business. The Company believes that these matters are either without merit or of a kind that should not Contractual Obligations Contractual obligations represent the Company's future cash commitments and liabilities under agreements with third one one may June 30, 2023

Note 16 - Stock Based Compensat

Note 16 - Stock Based Compensation	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	NOTE 16: On March 24, 2020, 2020 2020 No may 2020 10 2020 May 14, 2021, 2020 2020 June 30, 2023 On September 28, 2010, 2010 2010 2010 September 2020. may no The Company granted 4,230 and 6,691 options to purchase shares of common stock under the 2020 three six June 30, 2023, three six June 30, 2022, three six June 30, 2023 2022. three six June 30, 2023 2022 The fair value of stock options granted was calculated using the Black-Scholes option-pricing model applying the following assumptions: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Risk-free interest rate 3.27% 3.89% 2.87% 3.02% 3.27% 4.25% 1.86% 3.02% Expected term (in years) 5.31 - 6.16 5.19 - 6.11 5.31 - 6.16 5.19 - 6.11 Dividend yield - - - - Expected volatility 104% 129% 114% 126% 103% 129% 114% 128% The Company recognized stock-based compensation expense, which was included under the following captions in the Condensed Consolidated Statements of Operations: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 General and administrative $ 1,156 $ 1,140 $ 2,211 $ 2,323 Research and development 447 631 965 1,254 Total stock compensation expense $ 1,603 $ 1,771 $ 3,176 $ 3,577 In accordance the May 26, 2023 fifty three six June 30, 2023, not six Options issued and outstanding as of June 30, 2023, six June 30, 2023, Number of Underlying Shares Weighted-Average Exercise Price Per Share Weighted-Average Contractual Life Remaining in Years Aggregate Intrinsic Value Outstanding as of January 1, 2023 13,906 $ 2.35 Granted 6,691 $ 0.82 $ 27 Exercised - - Forfeited (419 ) $ 0.90 Expired (4 ) $ 870.40 Outstanding as of June 30, 2023 20,174 $ 1.68 8.12 $ 3,252 Exercisable as of June 30, 2023 12,823 $ 2.12 7.25 $ 489 Vested and expected to vest 20,174 $ 1.68 8.12 $ 3,252 On June 30, 2023 June 30, 2023 Defined Contribution Plan The Company has a defined contribution plan to which employees of the Company may may three six June 30, 2023 2022,

Note 17 - Subsequent Event

Note 17 - Subsequent Event	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 17: From July 1, 2023 August 10, 2023,

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form 10 10 01 X. not no 10 December 31, 2022 not In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included and have been prepared on the same basis as the annual consolidated financial statements. Operating results for the six June 30, 2023 not may December 31, 2023.
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassification Interest income has been reclassified from prior period amounts to conform to the current year presentation.
Use of Estimates, Policy [Policy Text Block]	Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Segment Reporting, Policy [Policy Text Block]	Segments The Company operates as a single
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash and cash equivalents include unrestricted cash and all highly liquid instruments with maturities of three
Equity Securities without Readily Determinable Fair Value [Policy Text Block]	Investments in Equity Securities The Company currently has one not ASC 321 Equity Once a decline in fair value is determined, an impairment charge is recorded to Impairment charge on investment in equity securities in the Condensed Consolidated Statement of Operations and a new basis in the investment is established. If market, industry, and/or investee conditions deteriorate, we may 4.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements The Company records financial assets and liabilities measured on a recurring and non-recurring basis, as well as all non-financial assets and liabilities subject to fair value measurement at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The accounting guidance establishes a hierarchy for inputs used in measuring fair value that minimizes the use of unobservable inputs by requiring the use of observable market data when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on active market data. Unobservable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. The fair value hierarchy is broken down into the three ● Level 1 ● Level 2 ● Level 3 no The carrying amounts reflected in the accompanying Condensed Consolidated Balance Sheets for cash and cash equivalents, restricted cash, prepaid expenses, research and development rebate receivable, other current assets, accounts payable, accrued expenses, payroll liabilities and other current liabilities approximate their fair values due to their short-term nature. Refer to Note 10.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development (R&D) costs are generally expensed as incurred. R&D expenses include, for example, manufacturing expenses for the Company's drugs under development, expenses associated with preclinical studies, clinical trials and associated salaries, bonuses, stock-based compensation and benefits. The Company has entered into various research and development contracts with research institutions, clinical research organizations (CROs), clinical manufacturing organizations (CMOs) and other companies. Payments for these activities are based on the terms of the individual agreements, which may may R&D expenses also include an allocation of the CEO's salary and related benefits, including bonus and non-cash stock-based compensation expense, based on an estimate of his total hours spent on R&D activities. The Company's CEO is involved in the development of the Company's drug candidates and oversight of the related clinical trial activity.
Share-Based Payment Arrangement [Policy Text Block]	Stock-based Payments The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers, non-employee directors, and other key persons providing services to the Company, currently limited to stock options. Stock compensation expense is based on the estimated grant date fair value and is recognized as an expense over the requisite service period. The Company has made a policy election to recognize forfeitures when they occur. The fair value of each stock option grant is estimated using the Black-Scholes option-pricing model, which requires assumptions regarding the expected volatility of the stock options, the expected life of the options, an expectation regarding future dividends on the Company’s common stock, and an estimate of the appropriate risk-free interest rate. The Company’s expected common stock price volatility assumption is based upon the historical volatility of its stock price. The Company has elected the simplified method for the expected life assumption for stock option grants, which averages the contractual term of the options of 10 years with the vesting term, typically one four not no
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation and Transactions The majority of the Company's operations occur in entities that have the U.S. dollar as their functional currency. Subsidiary assets and liabilities translated into U.S. dollars at rates of exchange in effect at the end of the period. Expense amounts are translated using the average exchange rates for the period.

Note 4 - Investment in Equity_2

Note 4 - Investment in Equity Securities (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Tables
Equity Securities without Readily Determinable Fair Value [Table Text Block]	Investment in equity securities: Beginning balance January 1, 2023 $ 4,700 Impairment charge on investment in equity securities (2,990 ) Ending balance June 30, 2023 $ 1,710

Note 6 - Prepaid Expenses (Tabl

Note 6 - Prepaid Expenses (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	As of June 30, As of December 31, 2023 2022 Prepaid research and development $ 4,918 $ 3,480 Prepaid insurance 509 387 Professional services 191 130 Other 141 34 Total prepaid expenses $ 5,759 $ 4,031

Note 8 - Accrued Expenses (Tabl

Note 8 - Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	As of June 30, As of December 31, 2023 2022 Research and development $ 559 $ 1,038 Professional Services 244 21 Total accrued liabilities $ 803 $ 1,059

Note 9 - Payroll Liabilities (T

Note 9 - Payroll Liabilities (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Tables
Schedule of Payroll Liabilities [Table Text Block]	As of June 30, As of December 31, 2023 2022 Accrued bonuses $ 507 $ 1,060 Accrued vacation 232 224 Accrued payroll 716 241 Total payroll liabilities $ 1,455 $ 1,525

Note 10 - Fair Value of Finan_2

Note 10 - Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	June 30, 2023 Estimated Fair Value Level 1 Level 2 Level 3 Assets: Money market account $ 97,182 $ 97,182 $ - $ - December 31, 2022 Estimated Fair Value Level 1 Level 2 Level 3 Assets: Money market account $ 102,681 $ 102,681 $ - $ -

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Outstanding Warrants to Purchase Shares Exercise Price Per Share Expiration Date December 2020 warrants 6,490 $ 1.00 December 11, 2024-June 21, 2025 January 2021 warrants 4,500 $ 1.055 July 8, 2025 March 2021 warrants 10,525 $ 2.88 September 22, 2025 21,515

Note 12 - Net Loss Per Share (T

Note 12 - Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Options to purchase common stock 17,828 13,337 16,294 12,219 Series B convertible preferred stock 165 165 165 165 Warrants to purchase common stock 21,515 22,009 21,515 22,142 39,508 35,511 37,974 34,526

Note 16 - Stock Based Compens_2

Note 16 - Stock Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Risk-free interest rate 3.27% 3.89% 2.87% 3.02% 3.27% 4.25% 1.86% 3.02% Expected term (in years) 5.31 - 6.16 5.19 - 6.11 5.31 - 6.16 5.19 - 6.11 Dividend yield - - - - Expected volatility 104% 129% 114% 126% 103% 129% 114% 128%
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Number of Underlying Shares Weighted-Average Exercise Price Per Share Weighted-Average Contractual Life Remaining in Years Aggregate Intrinsic Value Outstanding as of January 1, 2023 13,906 $ 2.35 Granted 6,691 $ 0.82 $ 27 Exercised - - Forfeited (419 ) $ 0.90 Expired (4 ) $ 870.40 Outstanding as of June 30, 2023 20,174 $ 1.68 8.12 $ 3,252 Exercisable as of June 30, 2023 12,823 $ 2.12 7.25 $ 489 Vested and expected to vest 20,174 $ 1.68 8.12 $ 3,252
Share-Based Payment Arrangement, Option [Member]
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 General and administrative $ 1,156 $ 1,140 $ 2,211 $ 2,323 Research and development 447 631 965 1,254 Total stock compensation expense $ 1,603 $ 1,771 $ 3,176 $ 3,577

Note 2 - Liquidity and Capita_2

Note 2 - Liquidity and Capital Resources (Details Textual) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Net Income (Loss) Attributable to Parent	$ (9,830)	$ (6,281)	$ (6,672)	$ (4,785)	$ (16,111)	$ (11,457)
Net Cash Provided by (Used in) Operating Activities					(11,487)	(10,827)
Cash and Cash Equivalents, at Carrying Value	99,390		$ 125,537		99,390	$ 125,537	$ 110,890
Working Capital (Deficit)	$ 102,525				$ 102,525

Note 3 - Summary of Accountin_2

Note 3 - Summary of Accounting Policies (Details Textual)	6 Months Ended
	Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0%
Number of Operating Segments	1
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Vesting Term (Year)	4 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Vesting Term (Year)	1 year

Note 4 - Investment in Equity_3

Note 4 - Investment in Equity Securities (Details Textual) $ in Thousands		3 Months Ended		6 Months Ended
	Dec. 23, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)
Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount		$ 2,990	$ 0	$ 2,990	$ 0
Measurement Input, Expected Term [Member]
Equity Securities without Readily Determinable Fair Value, Measurement Input		3.5		3.5
Measurement Input, Probability [Member] | Valuation, Dynamic Options Approach [Member]
Equity Securities without Readily Determinable Fair Value, Measurement Input		0.50		0.50
Measurement Input, Probability [Member] | Valuation, Cost Approach [Member]
Equity Securities without Readily Determinable Fair Value, Measurement Input		0.50		0.50
Dynamic Cell Therapies, Inc. [Member]
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage	19%
Dynamic Cell Therapies, Inc. [Member]
Payments to Acquire Equity Securities without Readily Determinable Fair Value	$ 4,700

Note 4 - Investment in Equity_4

Note 4 - Investment in Equity Securities - Summary of Changes in Fair Value Estimate (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Beginning balance			$ 4,700
Impairment charge on investment in equity securities	$ (2,990)	$ 0	(2,990)	$ 0
Ending balance	1,710		1,710
Fair Value, Inputs, Level 3 [Member]
Beginning balance			4,700
Impairment charge on investment in equity securities			(2,990)
Ending balance	$ 1,710		$ 1,710

Note 5 - Restricted Cash (Detai

Note 5 - Restricted Cash (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022
Restricted Cash and Cash Equivalents, Total	$ 110	$ 110	$ 110

Note 6 - Prepaid Expenses - Sch

Note 6 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Prepaid research and development	$ 4,918	$ 3,480
Prepaid insurance	509	387
Professional services	191	130
Other	141	34
Total prepaid expenses	$ 5,759	$ 4,031

Note 7 - Research and Develop_2

Note 7 - Research and Development Rebate Receivable (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Research and Development Expense	$ 3,705	$ 3,433	$ 7,213	$ 4,937
Research and Development Tax Rebate Receivable	737		737		$ 743
Atossa Genetics AUS Pty Ltd [Member]
Research and Development Expense	34	607	86	930
Research and Development Cash Rebate	0	629	0	629
Research and Development Tax Rebate Receivable	737		737		$ 743
Research and Development Expense, Reduced Amount Due to Tax Rebate	$ 10	$ 264	$ 37	$ 404

Note 8 - Accrued Expenses - Sch

Note 8 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Research and development	$ 559	$ 1,038
Professional Services	244	21
Total accrued liabilities	$ 803	$ 1,059

Note 9 - Payroll Liabilities -

Note 9 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Accrued bonuses	$ 507	$ 1,060
Accrued vacation	232	224
Accrued payroll	716	241
Total payroll liabilities	$ 1,455	$ 1,525

Note 10 - Fair Value of Finan_3

Note 10 - Fair Value of Financial Instruments (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Fair Value, Recurring [Member]
Financial Liabilities Fair Value Disclosure	$ 0	$ 0

Note 10 - Fair Value of Finan_4

Note 10 - Fair Value of Financial Instruments - Assets and Liabilities Measured on Recurring Basis (Details) - Fair Value, Recurring [Member] - Money Market Funds [Member] - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Money market account	$ 97,182	$ 102,681
Fair Value, Inputs, Level 1 [Member]
Money market account	97,182	102,681
Fair Value, Inputs, Level 2 [Member]
Money market account	0	0
Fair Value, Inputs, Level 3 [Member]
Money market account	$ 0	$ 0

Note 11 - Stockholders' Equit_2

Note 11 - Stockholders' Equity (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 27, 2023	Dec. 31, 2022	May 19, 2014
Number of Shares Authorized to Issue (in shares)	185,000,000		185,000,000
Common Stock, Shares Authorized (in shares)	175,000,000		175,000,000			175,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.18		$ 0.18			$ 0.18
Preferred Stock, Shares Authorized (in shares)	10,000,000		10,000,000			10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001		$ 0.001			$ 0.001
Stockholder Rights Agreement, Number of Preferred Stock Right Distributed for Each Share of Common Stock (in shares)							1
Stockholder Rights Agreement, Acquiring Person, Percentage of Ownership							15%
Stockholder Rights Agreement, Acquiring Person, Additional Percentage of Ownership							2%
Stockholder Rights Agreement, Initial Exercise Price of Each Right (in dollars per share)							$ 15
Stockholder Rights Agreement, Share Price (in dollars per share)							$ 30
Treasury Stock, Value, Acquired, Cost Method	$ 152,000
Treasury Stock, Common, Shares (in shares)	119,000		119,000			0
Preferred Stock, Shares Issued (in shares)	1,000		1,000			1,000
Consummate a Business Combination, Percentage of Acquired Outstanding Shares	50%		50%
Consummate a Business Combination, Percentage of Aggregate Ordinary Voting Power	50%		50%
Class of Warrant or Right, Outstanding (in shares)	21,515,000		21,515,000
Class of Warrant or Right, Exercised During Period (in shares)	0	0	0	0
The 2020 Liability Warrants [Member]
Warrants and Rights Outstanding, Term (Year)	4 years		4 years
Warrants Associated with 2020 Offering Consisting of Common Stock and Warrants [Member]
Warrants and Rights Outstanding, Term (Year)	4 years 6 months		4 years 6 months
The 2020 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1		1
Warrants Exercisable, Ownership Percentage of Company’s Shares Allowed	4.99%		4.99%
Common Stock, Convertible, Ownership Percentage of Company’s Shares Allowed	9.99%		9.99%
Class of Warrant or Right, Outstanding (in shares)	6,490,000		6,490,000
Series A Junior Participating Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)	750,000		750,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001		$ 0.001
Preferred Stock, Shares Issued (in shares)	0		0			0
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)	4,000		4,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001		$ 0.001
Preferred Stock, Shares Issued (in shares)	0		0			0
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)	25,000		25,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001		$ 0.001
Preferred Stock, Convertible, Conversion Price (in dollars per share)	$ 3.52		$ 3.52
Series C Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)	20,000		20,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001		$ 0.001
Preferred Stock, Shares Issued (in shares)	0		0			0
Stated Value per Share	$ 1,000		$ 1,000
Preferred Stock, Convertible, Ownership Percentage of Company’s Shares Allowed	9.99%		9.99%
Share Repurchase Program [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share)					$ 0.18
Stock Repurchase Program, Authorized Amount					$ 10,000,000
Treasury Stock, Shares, Acquired (in shares)			119,000
Treasury Stock, Value, Acquired, Cost Method			$ 152,000
Treasury Stock, Common, Shares (in shares)	119,000		119,000

Note 11 - Stockholders' Equit_3

Note 11 - Stockholders' Equity - Outstanding Warrants (Details) shares in Thousands	Jun. 30, 2023 $ / shares shares
Outstanding Warrants to Purchase Shares (in shares)	21,515
The 2020 Warrants [Member]
Outstanding Warrants to Purchase Shares (in shares)	6,490
Exercise Price (in dollars per share) | $ / shares	$ 1
The January 2021 Warrants [Member]
Outstanding Warrants to Purchase Shares (in shares)	4,500
Exercise Price (in dollars per share) | $ / shares	$ 1.055
March 2021 Warrants [Member]
Outstanding Warrants to Purchase Shares (in shares)	10,525
Exercise Price (in dollars per share) | $ / shares	$ 2.88

Note 12 - Net Loss Per Share -

Note 12 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Number of potential common shares excluded (in shares)	39,508	35,511	37,974	34,526
Share-Based Payment Arrangement, Option [Member]
Number of potential common shares excluded (in shares)	17,828	13,337	16,294	12,219
Series B Convertible Preferred Stock [Member]
Number of potential common shares excluded (in shares)	165	165	165	165
Warrant [Member]
Number of potential common shares excluded (in shares)	21,515	22,009	21,515	22,142

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Income Tax Expense (Benefit), Total	$ 0	$ 0	$ 0	$ 0	$ 0

Note 14 - Concentration of Cr_2

Note 14 - Concentration of Credit Risk (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Cash, Uninsured Amount	$ 99,208	$ 110,647

Note 15 - Commitments and Con_2

Note 15 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands			3 Months Ended		6 Months Ended
	Jun. 26, 2023	Jan. 01, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Lessee, Operating Lease, Monthly Rent Payments	$ 3	$ 2
Operating Lease, Expense			$ 3	$ 2	$ 7	$ 8
Research and Development Arrangement [Member]
Unrecorded Unconditional Purchase Obligation, to be Paid, Remainder of Fiscal Year			$ 908		$ 908

Note 16 - Stock Based Compens_3

Note 16 - Stock Based Compensation (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands			3 Months Ended		6 Months Ended
	May 26, 2023	May 14, 2021	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Mar. 24, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)					6,691
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)					0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares (in shares)			7,351		7,351
Defined Contribution Plan, Employer Matching Contribution, Percent of Match					6%
Defined Contribution Plan, Cost			$ 50	$ 36	$ 106	$ 68
Former Chief Financial Officer [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Percentage Outstanding	50%
Share-Based Payment Arrangement, Accelerated Cost	$ 320
Supplemental Unemployment Benefits, Severance Benefits	$ 554
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount			$ 5,297		$ 5,297
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)					2 years 4 months 6 days
The 2020 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)							3,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)		15,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			4,230	1,128	6,691	3,849
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)			$ 0.74	$ 0.80	$ 0.69	$ 0.99
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)			0	0	0	0
The 2020 Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)			1,979		1,979

Note 16 - Stock Based Compens_4

Note 16 - Stock Based Compensation - Valuation Assumptions (Details) - Share-Based Payment Arrangement, Option [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Minimum [Member]
Risk-free interest rate	3.27%	2.87%	3.27%	1.86%
Expected term (in years) (Year)	5 years 3 months 21 days	5 years 2 months 8 days	5 years 3 months 21 days	5 years 2 months 8 days
Expected volatility	104%	114%	103%	114%
Maximum [Member]
Risk-free interest rate	3.89%	3.02%	4.25%	3.02%
Expected term (in years) (Year)	6 years 1 month 28 days	6 years 1 month 9 days	6 years 1 month 28 days	6 years 1 month 9 days
Expected volatility	129%	126%	129%	128%

Note 16 - Stock Based Compens_5

Note 16 - Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Stock compensation expense	$ 1,603	$ 1,771	$ 3,176	$ 3,577
General and Administrative Expense [Member]
Stock compensation expense	1,156	1,140	2,211	2,323
Research and Development Expense [Member]
Stock compensation expense	$ 447	$ 631	$ 965	$ 1,254

Note 16 - Stock Based Compens_6

Note 16 - Stock Based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2023
Outstanding, shares (in shares)	13,906
Outstanding, weighted average exercise price per share (in dollars per share)	$ 2.35
Granted (in shares)	6,691
Granted, weighted average exercise price per share (in dollars per share)	$ 0.82
Granted, aggregate intrinsic value	$ 27
Exercised (in shares)	0
Exercised, weighted average exercise price per share (in dollars per share)	$ 0
Forfeited (in shares)	(419)
Forfeited, weighted average exercise price per share (in dollars per share)	$ 0.90
Expired (in shares)	(4)
Expired, weighted average exercise price per share (in dollars per share)	$ 870.40
Outstanding, shares (in shares)	20,174
Outstanding, weighted average exercise price per share (in dollars per share)	$ 1.68
Outstanding, weighted average contractual life remaining in years (Year)	8 years 1 month 13 days
Outstanding, aggregate intrinsic value	$ 3,252
Exercisable, shares (in shares)	12,823
Exercisable, Weighted average exercise price per share (in dollars per share)	$ 2.12
Exercisable, weighted average contractual life remaining in years (Year)	7 years 3 months
Vested and expected to vest, shares (in shares)	20,174
Vested and expected to vest, Weighted average exercise price per share (in dollars per share)	$ 1.68
Vested and expected to vest, weighted average contractual life remaining in years (Year)	8 years 1 month 13 days
Vested and expected to vest, aggregate intrinsic value	$ 3,252

Note 17 - Subsequent Event (Det

Note 17 - Subsequent Event (Details Textual) - USD ($) shares in Thousands, $ in Thousands	1 Months Ended	3 Months Ended	6 Months Ended
	Aug. 10, 2023	Jun. 30, 2023	Jun. 30, 2023
Treasury Stock, Value, Acquired, Cost Method		$ 152
Share Repurchase Program [Member]
Treasury Stock, Shares, Acquired (in shares)			119
Treasury Stock, Value, Acquired, Cost Method			$ 152
Share Repurchase Program [Member] | Subsequent Event [Member]
Treasury Stock, Shares, Acquired (in shares)	720
Treasury Stock, Value, Acquired, Cost Method	$ 868